Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SL 28

Next Previous
Drug Profile

SL 28

Alternative Names: SL-28

Latest Information Update: 21 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Second Life Therapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Leukocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuroblastoma

Most Recent Events

  • 15 Jan 2026 Second Life Therapeutics plans a phase-I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Unresectable/Inoperable) in Australia (IV) (NCT07341737),
  • 20 Mar 2025 Preclinical trials in Neuroblastoma (In children, In adolescents, Second-line therapy or greater) in USA (IV)
  • 12 Mar 2025 Second Life Therapeutics plans a expanded access for Neuroblastoma (In children, In adolescents, Second-line therapy or greater) in the USA (IV) (NCT06872489)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top